Cargando…

Heart-type Fatty acid-binding protein in Acute Myocardial infarction Evaluation (FAME): Background and design of a diagnostic study in primary care

BACKGROUND: Currently used biomarkers for cardiac ischemia are elevated in blood plasma after a delay of several hours and therefore unable to detect acute coronary syndrome (ACS) in a very early stage. General practitioners (GPs), however, are often confronted with patients suspected of ACS within...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruins Slot, Madeleine HE, van der Heijden, Geert JMG, Rutten, Frans H, van der Spoel, Onno P, Mast, E Gijs, Bredero, Ad C, Doevendans, Pieter A, Glatz, Jan FC, Hoes, Arno W
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2358877/
https://www.ncbi.nlm.nih.gov/pubmed/18412949
http://dx.doi.org/10.1186/1471-2261-8-8
_version_ 1782152860677439488
author Bruins Slot, Madeleine HE
van der Heijden, Geert JMG
Rutten, Frans H
van der Spoel, Onno P
Mast, E Gijs
Bredero, Ad C
Doevendans, Pieter A
Glatz, Jan FC
Hoes, Arno W
author_facet Bruins Slot, Madeleine HE
van der Heijden, Geert JMG
Rutten, Frans H
van der Spoel, Onno P
Mast, E Gijs
Bredero, Ad C
Doevendans, Pieter A
Glatz, Jan FC
Hoes, Arno W
author_sort Bruins Slot, Madeleine HE
collection PubMed
description BACKGROUND: Currently used biomarkers for cardiac ischemia are elevated in blood plasma after a delay of several hours and therefore unable to detect acute coronary syndrome (ACS) in a very early stage. General practitioners (GPs), however, are often confronted with patients suspected of ACS within hours after onset of complaints. This ongoing study aims to evaluate the added diagnostic value beyond clinical assessment for a rapid bedside test for heart-type fatty-acid binding protein (H-FABP), a biomarker that is detectable as soon as one hour after onset of ischemia. METHODS: Participating GPs perform a blinded H-FABP rapid bedside test (Cardiodetect(®)) in patients with symptoms suggestive of ACS such as chest pain or discomfort at rest. All patients, whether referred to hospital or not, undergo electrocardiography (ECG) and venapunction for a plasma troponin test within 12–36 hours after onset of complaints. A final diagnosis will be established by an expert panel consisting of two cardiologists and one general practitioner (blinded to the H-FABP test result), using all available patient information, also including signs and symptoms. The added diagnostic value of the H-FABP test beyond history taking and physical examination will be determined with receiver operating characteristic curves derived from multivariate regression analysis. CONCLUSION: Reasons for presenting the design of our study include the prevention of publication bias and unacknowledged alterations in the study aim, design or data-analysis. To our knowledge this study is the first to assess the diagnostic value of H-FABP outside a hospital-setting. Several previous hospital-based studies showed the potential value of H-FABP in diagnosing ACS. Up to now however it is unclear whether these results are equally promising when the test is used in primary care. The first results are expected in the end of 2008.
format Text
id pubmed-2358877
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-23588772008-04-29 Heart-type Fatty acid-binding protein in Acute Myocardial infarction Evaluation (FAME): Background and design of a diagnostic study in primary care Bruins Slot, Madeleine HE van der Heijden, Geert JMG Rutten, Frans H van der Spoel, Onno P Mast, E Gijs Bredero, Ad C Doevendans, Pieter A Glatz, Jan FC Hoes, Arno W BMC Cardiovasc Disord Study Protocol BACKGROUND: Currently used biomarkers for cardiac ischemia are elevated in blood plasma after a delay of several hours and therefore unable to detect acute coronary syndrome (ACS) in a very early stage. General practitioners (GPs), however, are often confronted with patients suspected of ACS within hours after onset of complaints. This ongoing study aims to evaluate the added diagnostic value beyond clinical assessment for a rapid bedside test for heart-type fatty-acid binding protein (H-FABP), a biomarker that is detectable as soon as one hour after onset of ischemia. METHODS: Participating GPs perform a blinded H-FABP rapid bedside test (Cardiodetect(®)) in patients with symptoms suggestive of ACS such as chest pain or discomfort at rest. All patients, whether referred to hospital or not, undergo electrocardiography (ECG) and venapunction for a plasma troponin test within 12–36 hours after onset of complaints. A final diagnosis will be established by an expert panel consisting of two cardiologists and one general practitioner (blinded to the H-FABP test result), using all available patient information, also including signs and symptoms. The added diagnostic value of the H-FABP test beyond history taking and physical examination will be determined with receiver operating characteristic curves derived from multivariate regression analysis. CONCLUSION: Reasons for presenting the design of our study include the prevention of publication bias and unacknowledged alterations in the study aim, design or data-analysis. To our knowledge this study is the first to assess the diagnostic value of H-FABP outside a hospital-setting. Several previous hospital-based studies showed the potential value of H-FABP in diagnosing ACS. Up to now however it is unclear whether these results are equally promising when the test is used in primary care. The first results are expected in the end of 2008. BioMed Central 2008-04-15 /pmc/articles/PMC2358877/ /pubmed/18412949 http://dx.doi.org/10.1186/1471-2261-8-8 Text en Copyright © 2008 Bruins Slot et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Bruins Slot, Madeleine HE
van der Heijden, Geert JMG
Rutten, Frans H
van der Spoel, Onno P
Mast, E Gijs
Bredero, Ad C
Doevendans, Pieter A
Glatz, Jan FC
Hoes, Arno W
Heart-type Fatty acid-binding protein in Acute Myocardial infarction Evaluation (FAME): Background and design of a diagnostic study in primary care
title Heart-type Fatty acid-binding protein in Acute Myocardial infarction Evaluation (FAME): Background and design of a diagnostic study in primary care
title_full Heart-type Fatty acid-binding protein in Acute Myocardial infarction Evaluation (FAME): Background and design of a diagnostic study in primary care
title_fullStr Heart-type Fatty acid-binding protein in Acute Myocardial infarction Evaluation (FAME): Background and design of a diagnostic study in primary care
title_full_unstemmed Heart-type Fatty acid-binding protein in Acute Myocardial infarction Evaluation (FAME): Background and design of a diagnostic study in primary care
title_short Heart-type Fatty acid-binding protein in Acute Myocardial infarction Evaluation (FAME): Background and design of a diagnostic study in primary care
title_sort heart-type fatty acid-binding protein in acute myocardial infarction evaluation (fame): background and design of a diagnostic study in primary care
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2358877/
https://www.ncbi.nlm.nih.gov/pubmed/18412949
http://dx.doi.org/10.1186/1471-2261-8-8
work_keys_str_mv AT bruinsslotmadeleinehe hearttypefattyacidbindingproteininacutemyocardialinfarctionevaluationfamebackgroundanddesignofadiagnosticstudyinprimarycare
AT vanderheijdengeertjmg hearttypefattyacidbindingproteininacutemyocardialinfarctionevaluationfamebackgroundanddesignofadiagnosticstudyinprimarycare
AT ruttenfransh hearttypefattyacidbindingproteininacutemyocardialinfarctionevaluationfamebackgroundanddesignofadiagnosticstudyinprimarycare
AT vanderspoelonnop hearttypefattyacidbindingproteininacutemyocardialinfarctionevaluationfamebackgroundanddesignofadiagnosticstudyinprimarycare
AT mastegijs hearttypefattyacidbindingproteininacutemyocardialinfarctionevaluationfamebackgroundanddesignofadiagnosticstudyinprimarycare
AT brederoadc hearttypefattyacidbindingproteininacutemyocardialinfarctionevaluationfamebackgroundanddesignofadiagnosticstudyinprimarycare
AT doevendanspietera hearttypefattyacidbindingproteininacutemyocardialinfarctionevaluationfamebackgroundanddesignofadiagnosticstudyinprimarycare
AT glatzjanfc hearttypefattyacidbindingproteininacutemyocardialinfarctionevaluationfamebackgroundanddesignofadiagnosticstudyinprimarycare
AT hoesarnow hearttypefattyacidbindingproteininacutemyocardialinfarctionevaluationfamebackgroundanddesignofadiagnosticstudyinprimarycare